Integrating In Vitro Analytics for Improved Antibody–Drug Conjugate Candidate Selection
These findings highlight the critical need for integrated in vitro analytics and computational tools in efficient ADC development, supporting the selection of candidates with the greatest potential for clinical success and facilitating a more effective and accelerated path from discovery to clinical application.
Authors
- Mahammad Ahmed (ORCID: https://orcid.org/0000-0002-5627-8648)
- David Tickle
- Leigh Hostetler
- Virginia del Solar (ORCID: https://orcid.org/0000-0001-9405-674X)
- Chao Gong (ORCID: https://orcid.org/0000-0001-7196-5588)
- Lena Sokol Becciolini
- Gyoung Dong Kang
- Angel Zhang
- Balakumar Vijayakrishnan
- Akbar H. Khan
- Maximilliam Lee
- Abhisek Mitra
- Bianka Jackowska
- Yan Hu
- Ali Saleh
- Annarita Di Tacchio
Institutions
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Japan) (JP)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-03
- DOI
- https://doi.org/10.3390/cancers18010164
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00